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A nested PCR was developed for the detection of Borrelia burgdorferi-specific DNA in the urine of patients
with erythema migrans. The target for the nested PCR was a specific region of the flagellin gene; the detection
limit was less than five organisms of B. burgdorferi including all three species B. burgdorferi sensu stricto, B.
afzelii, and B. garinii. A prospective, controlled, blinded study was performed with 26 patients with erythema
migrans to evaluate the nested PCR method with clinical samples. B. burgdorferi-specific DNA could be
detected in urine specimens from 22 of 24 patients with erythema migrans (sensitivity, 91.67%). Immediately
after therapy, 11 of 19 patients still yielded positive results (58%). Eight weeks after therapy, 2 of 16 patients
(13%) were positive by PCR of urine, and 20 weeks after treatment none of seven investigated urine samples
was reactive. Essential for the sensitivity that was obtained was the development of a simple DNA extraction
procedure. The results of the study indicate that the described method is highly sensitive and allows for the
effective control of the efficacy of antibiotic therapy in patients with early Lyme borreliosis.
Erythema migrans (EM), a typical skin lesion, is the first
clinical sign of infection with Borrelia burgdorferi in most pa-
tients after a tick bite. This clinical symptom is usually suffi-
cient for diagnosis. However, in a substantial number of pa-
tients, this skin eruption may not occur, may be atypical, or
may be missed. Under such circumstances, correct laboratory
diagnosis becomes important. Current methods, e.g., serology
or culture, are unsatisfactory (for a review, see reference 26),
and in addition, no single parameter that can be used to mon-
itor the efficacy of antimicrobial therapy is yet available.
PCR has gained importance for the diagnosis of Lyme bor-
reliosis (LB) since the first amplification of a chromosomal
DNA of B. burgdorferi (20). PCR is able to detect B. burgdor-
feri-specific DNA in a variety of clinical specimens from pa-
tients with both early and chronic manifestations of LB. Most
reports about the application of PCR to urine specimens from
patients with LB refer to patients with neuroborreliosis or late
disease (3, 7, 10) and Lyme arthritis (3, 12, 30). PCR has
already been performed on serum (5, 12) and skin lesions from
patients with EM (11, 16–18, 23, 27, 29), but only a few,
preliminary observations exist about investigations of urine
(11, 25). We report here on 26 consecutively diagnosed cases of
EM in patients residing in an area where borrelial infections
are endemic (Styria, Austria). Urine specimens from most of
these patients were obtained before and directly after antibi-
otic treatment. For these patients, additional samples were
also acquired 8 and 20 weeks after therapy. Urine specimens
were analyzed for B. burgdorferi-specific DNA by a newly de-
veloped nested PCR procedure.
MATERIALS AND METHODS
Patients. Twenty-six consecutively diagnosed patients (8 males and 18 females,
mean age, 56 years) with EM were seen from April to October 1993 at the
University Hospital Department of Dermatology in Graz, Austria. EM was
diagnosed on clinical grounds. A 4-mm punch biopsy specimen from the border
of the EM lesion was obtained, and specimens from 24 of 26 patients were
examined histopathologically to confirm the clinical diagnosis. Patients 22 and
25, who had clinically unequivocal EM lesions, refused a punch biopsy. None of
the 26 patients included in the study had received antibiotic therapy. Sixteen
patients presented with the annular type of EM (i.e., a peripheral ringlike
erythema), and 10 patients presented with the macular type of EM (i.e., a
homogeneous erythema with a bluish red center). The mean duration of EM
before the first presentation was 27 days (range, 4 to 100 days). Fourteen of 26
patients (54%) were classified as suffering from early disseminated LB and
exhibited no additional signs and symptoms. All patients resided in a geographic
area where LB is endemic (Styria, Austria). Twenty of 26 patients (77%) could
recall an arthropod bite at the same site where EM later developed. The mean
time period from the anthropod bite to the appearance of EM was 22 days
(range, 4 to 90 days) in these 20 patients. Three patients (patients 2, 4, and 20)
had suffered multiple tick or insect bites within an 8-week period before EM
occurred (see Table 1). On the first hospital visit, a midstream urine specimen
was obtained from all patients.
The patients were reexamined at the end of antibiotic therapy (minocycline at
100 mg orally twice daily for 14 days). Midstream urine specimens could be
obtained from 19 patients. A second clinical reevaluation of 22 patients took
place 8 weeks after the end of therapy; midstream urine specimens were obtained
from 16 of these 22 patients.
Thirteen patients were again reexamined 20 weeks after the end of therapy.
Midstream urine specimens were attained from seven of these patients.
Midstream urine specimens from 62 patients with various dermatological
disorders (Kaposi’s sarcoma, urticaria, and verruca) served as controls.
Bacterial strains. The following strains were used for susceptibility testing: B.
burgdorferi sensu stricto strains B31 (ATCC 35211), HB1, and H3; Borrelia garinii
PBi; Borrelia afzelii H1, H6, H10, and PKo (PBi and Pko strains were kindly
supplied by V. Preac-Mursic, University of Munich, Munich, Germany); Borrelia
japonicaHO14 (kindly supplied by T. Masuzawa, University of Shizuoka, Japan);
and five yet untyped strains isolated in Vienna from skin lesions from patients
with EM (strains H17, H19, H20, H21, and H22). Treponema pallidum Nichols,
Treponema denticola ATCC 33520, and Borrelia hermsii ATCC 35209, in addition
to clinical isolates of Chlamydia trachomatis, Gardnerella vaginalis, Neisseria gon-
orrhoeae, Mycoplasma hominis, Pseudomonas aeruginosa, and Ureaplasma urea-
lyticum, were used to assess the specificity of the nested PCR.
Preparation of urine samples for PCR. Urine specimens were frozen at
2708C, coded, and sent to the laboratory packed in dry ice. After thawing and
equilibration at 308C, 8 ml of the urine samples was centrifuged at 14,0003 g for
30 min. The pellet was resuspended in 600 ml of phosphate-buffered saline (PBS;
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pH 8.0), and the mixture was stored at 2708C. For analysis, 300 ml was centri-
fuged at 14,000 3 g for 20 min and the resulting pellet was dissolved in 50 ml of
PBS. A total of 50 ml of a 10% Chelex-100 suspension (Bio-Rad, Richmond,
Calif.) was added to the sample before it was heated at 1008C for 5 min and
subsequently chilled on ice; after centrifugation (3,000 3 g, 1 min), 10 ml of the
supernatant was used as the source of template DNA in the first PCR.
Nested PCR assay. Two nested PCRs, a heminested PCR and a nested PCR
targeting the chromosomal flagellin gene of B. burgdorferi (GenBank accession
no. X15661 [2]), were tested. In the heminested PCR assay (PCR-A in Fig. 1), an
outer primer pair, BBSCH1 (AGC ATC ACT TTC AGG GTC TC) and BBSCH2
(TGT CAT TGT AGC ATC TTT TAT TT), representing positions 483 to 502 and
903 to 881, respectively, and an inner primer pair, BBSCH1 and BBSCH4 (CCT
CAC CAG AGA AAA GAT T), representing positions 602 to 584, were used. The
first PCRwith the outer primers was run for 25 cycles with an annealing temperature
of 528C (30 s) in a total volume of 60 ml. Elongation and denaturation took place at
728C for 60 s and at 948C for 30 s. The reaction mixture contained 50 mM KCl, 1.5
mM magnesium chloride, 10 mM Tris-HCl (pH 8.3), 0.05% glycerol, 0.1% Triton
X-100, 0.1 mM EDTA, 0.1% bovine serum albumin, 200 mM (each) desoxynucle-
otide triphosphate (dAMP, dCTP, dTTP, and dGTP), 50 pM (each) outer primers,
2.0 U of Taq polymerase (Amplitaq; Perkin-Elmer, Norwalk, Conn.), and 10ml of
the DNA preparation. The mixture was overlaid with 1 drop of mineral oil. The
amplification reactions were performed in 200-ml thin-walled tubes with attached
caps either in a Gene AMP PCR system 9600 (Perkin-Elmer) or in a PTC-100-96
thermocycler with a hot bonnet (MJ-Research; Watertown, Mass.). Three microli-
ters from the first PCR mixture was transferred with a pipette with a disposable
piston into the 50-ml reaction mixture of the second PCR mixture containing the
same reactants used in the first PCR mixture, but with 25 pM (each) the inner
primers. The second PCR was done with 35 cycles of the same durations and at the
same temperatures as those used in the first PCR, yielding 120-bp product.
For the nested PCR (PCR-B in Fig. 1), 50 pM (each) the outer primers, of the
flagellin gene (2), primers BBSCH31 (CAC ACC AGC ATC ACT TTC AGG
GTC T) and BBSCH42 (CAA CCT CAT CTG TCA TTG TAG CAT CTT TTA
TTT), representing positions 477 to 501 and 913 to 881, respectively, the same
master mixture used in the first PCR, and 10 ml of DNA preparation were used.
The total volume was adjusted to 60 ml with water. The mixture was overlaid with
1 drop of mineral oil. The amplification reactions of the first PCR consisted of
25 cycles with denaturation at 948C for 30 s, annealing at 558C for 30 s, and
extension at 728C for 30 s. Thermocycling was preceded by 1 min at 958C; this was
followed by a final 10 min of extension at 728C. After amplification, 3 ml of the
first PCR mixture was transferred to a second PCR mixture consisting of the
same master mixture described above, but instead of outer primers, 25 pM (each)
the inner primers FL-59 (TTT CAG GGT CTC AGG CGT CTT) and FL-7
(GCA TTT TCA ATT TTA GCA AGT GAT G), representing positions 491 to
511 and 767 to 743, respectively, as modified from the primers of Picken (19),
were used, yielding a 277-bp amplicon. The second PCR was done with 35 cycles
of the same durations and at the same temperatures used for the first PCR for
denaturation and elongation, but the annealing temperature was increased to 588C.
The same number of blank controls, which contained 5 ml of water substituted
for DNA, as patient samples, as well as a positive control sample with 50 copies
of B. burgdorferi B31 DNA and DNA samples from uninfected patients as well as
two infected patients, were run in parallel with each amplification assay. If any of
the blank controls or samples from uninfected patients was found to be positive,
the whole run was repeated. Positive results were verified by a repeat PCR
starting with a second urine extraction. Negative results were checked for inhi-
bition by a newly developed assay.
Extraction of DNA, preparation of PCR mixtures, amplification, and analysis
of the amplicons were each done in separate areas. Filter-barrier pipette tips and
a dedicated set of pipettors were used to prepare all samples. Setting up of the
inner PCR was done in a PCR workstation (CBS, Del Mar, Calif.), which was
used only for this reaction step. Positive-displacement pipettes with disposable
pistons were used to prepare the PCR mixture. After each run the workstation
was cleaned with an aqueous hypochloric solution.
Amplified products (10 ml of hypochlorite) were resolved by 2% agarose gel
electrophoresis (NuSieve/SeaKem, 3:1; FMC Corporation, Rockland, Maine) at
150 V for 25 min. The gel was then stained with ethidium bromide and the bands
were visualized under UV illumination at 254 nm.
All laboratory investigations were performed without knowledge of donor
clinical data, nor was it known if the urine was from a presumably infected
patient or from a control subject.
Inhibition assay. In order to exclude inhibition of the polymerase reaction for
samples with nonreactive results, all PCR-negative samples were analyzed as
follows. A total of 100 copies of an internal standard were added to the first PCR
mixture. This standard was constructed by designing 40-mer primers for a 240-bp
nonhomologous region of a 0.6 kb BamHI-EcoRI fragment of the v-erbB gene
(PCR MIMIC Construction Kit; catalog no. K1700-1; Clontech, Palo Alto, Ca-
lif.) (24). The inner 20 oligonucleotides were complementary to the v-erbB
fragment, and the outer 20 oligonucleotides were complementary to the B. burg-
dorferi amplicon generated in the first PCR. With this internal standard, specific
primers BBSCH1-BBSCH2 amplify a 240-bp amplicon, if no inhibition of the
polymerase occurs. All samples that failed to amplify a 240-bp product were
considered inhibitory and were excluded from the study.
Serology. Analysis for immunoglobulin G (IgG) and IgM antibodies to B.
burgdorferi was performed on the day of the first hospital visit and routinely at the
first and third reexaminations. Purified, native flagellum of B. burgdorferi DK-1
isolated from a human EM lesion (DAKOPATTS ELISA Kit; DAKO Diagnos-
tika GmbH, Hamburg, Germany) was used as the test antigen (6).
RESULTS
All B. burgdorferi sensu stricto, B. garinii, B. afzelii, and B.
japonica isolates and the five yet untyped strains isolated from
skin lesions from patients with EM in Vienna could be ampli-
fied by both nested PCRs. The detection limit was less than five
organisms per PCR for all strains tested. Under the experi-
mental conditions, no reaction occurred with T. pallidum, T. den-
ticola, B. hermsii, C. trachomatis, G. vaginalis, N. gonorrhoeae, M.
hominis, P. aeruginosa, or U. urealyticum (data not shown).
B. burgdorferi-specific DNA was found in 22 of 24 urine
samples from untreated patients with EM by both nested PCRs
(Table 1). However, because of the higher annealing temper-
ature of PCR-B, the resulting 277-bp amplicon was always
strong, whereas the 120-bp amplicon of the heminested PCR-
A was generally weaker and the result of PCR-A was classified
as borderline for three patients (patients 4, 5, and 14 in Fig. 1).
Essential for the high sensitivity of the nested PCR was the
DNA preparation, because only samples boiled in the presence
of Chelex-100 showed specific amplicons (Fig. 1).
Inhibition was found for 2 of the 26 urine samples tested
completely (from patients 17 and 21), and the results for these
samples had to be excluded from the analysis. Three of the 62
control urine samples were positive, and additional urine sam-
ples taken from these patients, one with a diagnosis of Kaposi’s
sarcoma, one with scleroderma, and one with papules on the
nose, all of which were antibody negative and without a history of
tick bite, were found to be nonreactive, indicating carryover con-
tamination from the first urine samples. All three false-positive
urine samples were found within the first 2 weeks of the study,
and precautions for avoiding contaminations were, up to then,
found to be effective, because no other single false-positive sam-
ples could be detected during the study. Thus, the following
values concerning the nested PCR applied in the present study
could be calculated: sensitivity, 91.67%; specificity, 95.16%.
Thirteen of the 22 patients (59%) with a reactive urine
sample showed additional signs and symptoms as a result of
early disseminated LB. Nine of the 22 patients (41%) had no
extracutaneous manifestations. One patient (patient 25), for
whom the urine PCR yielded a negative result, presented with
flulike symptoms. The second patient (patient 13) with a neg-
ative urine PCR result was otherwise healthy. No differences
regarding further anamnestic or clinical data between patients
with reactive and nonreactive urine samples could be found.
IgG antibodies to B. burgdorferi were found by enzyme-
linked immunosorbent assay (ELISA) in the sera of 8 of the 22
patients (36%) whose urine tested positive by PCR; IgM an-
tibodies in the sera of 3 of these patients (14%) were found by
ELISA. On the other hand, a positive IgG antibody titer for B.
burgdorferi could be detected in one of the two patients with a
negative urine PCR result, both of whom had a negative result
for B. burgdorferi IgM antibodies.
The results obtained after treatment are summarized in Ta-
ble 2. Eleven of 19 urine samples obtained directly after anti-
biotic therapy contained B. burgdorferi-specific DNA (58%).
The PCR result for all of these 11 patients before therapy was
also positive. The urine of six patients that initially yielded a
positive PCR result showed no more reactivity directly after
therapy. For nine patients no direct comparison was possible
because of missing data or inhibition, as mentioned above.
Three of 11 patients (27%) with PCR-reactive urine samples
directly after therapy had a residual erythema and slight extra-
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cutaneous symptoms. Five of these 11 patients (46%) showed
a residual erythema but suffered from no additional signs and
symptoms. Another three patients were completely healthy
and their EM lesions had totally cleared. Three of the six
patients who had a negative urine PCR result directly after
therapy still had a residual erythema, and one of them had a
residual erythema plus headache; the other two patients had
no clinical symptoms.
A positive IgG antibody titer for B. burgdorferi was measured
by ELISA in the sera of 4 of the 11 urine PCR-positive patients
(36%). On the other hand, a positive IgG antibody titer for B.
burgdorferi could be detected by ELISA in the sera of three of
the eight patients (38%) with a negative urine PCR result. A
positive IgM titer could be found in the serum of only one
patient (patient 8), who was clinically healthy and who still had
a positive urine PCR result.
Twenty-two patients were again seen 8 weeks after therapy.
For 16 of these 22 patients, midstream urine specimens were
investigated for B. burgdorferi-specific DNA by PCR. Speci-
mens from only 2 of these 16 patients (13%) were still positive.
However, both patient with positive urine specimens (patients
15 and 16) were completely healthy at this time and no longer
had EM lesions. Serological data were not available for these
patients. On the other hand, patient 6, who still had residual
EM lesions 8 weeks after treatment, did not show any B.
burgdorferi-specific DNA in his urine sample.
Urine samples for PCR investigation could be obtained from
7 of 13 patients who could be followed up until 20 weeks after
the end of antibiotic treatment. These specimens, all of which
were obtained from then clinically healthy patients, yielded neg-
ative results. Interestingly, the sera of two of the patients (pa-
tients 3 and 6) had a positive IgM antibody titer for B. burg-
dorferi by ELISA, in contrast to their preceding serologic analyses.
The serum of another urine PCR-negative patient (patient 16)
still had a positive IgG antibody titer for B. burgdorferi ELISA.
DISCUSSION
PCR-based technology has been successfully used for the
detection of B. burgdorferi specific DNA in patients with dif-
FIG. 1. Influence of DNA preparation on PCR. A centrifuged and washed
urine sample from one infected patient was boiled with (lanes 2 and 3) or without
(lanes 4 and 5) Chelex-100 and was amplified by heminested PCR (PCR-A; lanes
3 and 5) and nested PCR (PCR-B; lanes 2 and 4). Electrophoretic separation of
PCR products on a 2% agarose gel is shown together with two markers, a
homemade marker with 120-, 277-, and 341-bp fragments (lane 1) and a marker
from Bio Ventures, Inc., Murfreesboro, Tenn., with linear, double-stranded
DNA bands from 50 to 1,000 bp, as indicated on the right (lane 7). Lane 6,
positive control. B. burgdorferi-specific bands (120 bp by heminested PCR and
277 bp by nested PCR) can be seen only with the DNA preparation that included
Chelex-100.
TABLE 1. Clinical and laboratory data for patients with EM before antibiotic therapya
Patient
no. Sex
Age
(yr)
Arthro-
pod bite
Time from
arthropod bite
to EM (days)
Site of
EM
Type of
EM
Size of
EM (cm)
Duration of EM
before first
visit (days)
Additional signs
and symptoms
S Bb
IgG Ab
S Bb
IgM Ab
Bb DNA
in urine
specimen
1 F 48 T 28 Right shoulder M 16 3 16 28 N 1 1 1
2 F 63 Tb UK Right buttock A 213 12 60 H, M 1 1 1
3 F 70 T 60 Lower abdomen A 60 3 16 15 N 2 2 1
4 F 79 Ib UK Left thigh A 123 7 6 F 2 2 1
5 F 61 T 90 Lower abdomen M 20 3 15 40 N 1 2 1
6 F 53 T 11 Right thigh A 15 3 11 10 ST 2 2 1
7 F 81 T 8 Left thigh M 26 3 26 20 N 1 2 1
8 F 59 T 8 Right knee M 10 3 6 4 N 2 2 1
9 F 49 I 14 Right shoulder A 24 3 16 28 H, AR 2 2 1
10 F 60 I 12 Lower abdomen A 22 3 12 18 J, M 2 2 1
11 F 84 Left shoulder A 303 20 25 N 2 2 1
12 F 54 T 14 Left thigh A 29 3 29 70 L 1 2 1
13 M 57 Upper thorax A 163 14 21 N 2 2 2
14 F 34 I 5 Right thigh A 13 3 10 6 N 2 2 1
15 F 29 T 30 Lower back A 34 3 28 28 F, AR 1 1 1
16 M 46 I 10 Right thigh M 16 3 16 7 F, H 1 2 1
17 F 52 T 25 Right buttock A 17 3 15 42 N 2 2 Inhibited
18 F 56 I 7 Right thigh A 17 3 11 21 AR 2 2 1
19 M 55 Right thigh A 163 15 25 TE, F, AR, M 2 2 1
20 M 51 Tb UK Left thigh M 163 6 22 F, H 2 2 1
21 M 52 T 30 Left upper arm A 14 3 11 100 N 1 2 Inhibited
22 M 70 T 5 Left knee M 30 3 17 10 N 1 2 1
23 M 63 T 40 Upper thorax A 20 3 12 26 N 2 2 1
24 M 71 I 4 Right buttock M 7 3 6 17 TE 2 2 1
25 F 20 T 10 Lower abdomen M 7 3 5 4 TE, F, SR, H, M 1 2 2
26 F 36 T 26 Lower back M 18 3 8 50 F, H 2 2 1
a Abbreviations: F, female; M, male, T, tick; I, insect; UK, unknown, M, macular type of EM; A, annular type of EM; N, none; H, headache; M, myalgias; F, fatigue; ST,
sore throat; AR, arthralgias; J, temporomandibular pain; L, regional lymphadenopathy, TE, fever;Bb, B. burgdorferi; Ab, antibodies. A total of 26 patients were examined.
bMultiple tick or insect bites. Date of last one could not be recalled exactly.
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ferent manifestations of LB in a variety of body tissues and
fluids. There are reports of PCR investigations of serum (5,
12), blood (25), and skin lesions (11, 16, 23, 25, 27, 29) from
patients with EM. B. burgdorferi disseminates early in the
course of the disease. Thus, urine from patients with EM also
might be a suitable clinical source for B. burgdorferi-specific
PCR. The following facts support this assumption. (i) B. burg-
dorferi DNA could be found by culture and PCR in renal and
urinary bladder tissue from white-footed mice (Peromyscus leu-
copus) living in areas where LB is endemic (14, 22). (ii) The
detection of B. burgdorferi components in urine by immune
capture methods or inhibition ELISA has been reported for
animal models and patients with LB (1, 8). Magnarelli and
coworkers (13) recently found B. burgdorferi antigens in urine
specimens from 8 of 28 patients with EM by an inhibition
ELISA (28.6%). (iii) Very low numbers of B. burgdorferi or-
ganisms could be detected in urine samples in vitro by PCR
analysis (15). Furthermore, multiple urine specimens can easily
be obtained during the course of the disease.
However, only a few, preliminary reports exist about the
application of PCR to urine specimens in humans with early
LB. Lebech et al. (11) found B. burgdorferi-specific DNA in
urine samples from 3 of 29 (10%) untreated, consecutively
diagnosed patients with EM by using a PCR based on the
amplification of a fragment of the 16S rRNA gene. Sun et al.
(25) obtained positive results for 18 and 21% of 23 patients
with EM by testing pretreatment urine samples in duplicate by
the same method used by Lebech et al. (11). The authors
concluded from this low sensitivity that urine is not a suitable
reservoir for the detection of B. burgdorferi.
In order to improve B. burgdorferi detection by PCR, two
assumptions had to be proved: (i) All three species of B.
burgdorferi, B. burgdorferi sensu stricto, B. afzelii, and B. garinii,
should be detected with similar sensitivities. This was possible
with targets from the flagellin gene. Recently, it was shown
(17) that the sensitivity of PCR with the ospA gene as the target
varied by up to 103 with different strains. (ii) Sensitivity should
be high in order to obtain reproducible results for specimens
containing only a limited number of organisms.
Urine samples from infected patients amplified by standard
PCR gave inconsistent results, and sensitivity was low (,40%;
data not shown). Therefore, nested PCRs were tested. In ad-
dition to their higher levels of sensitivity and specificity, nested
PCRs have been shown to be able to replace hybridization reac-
tions for confirmation of the results (31). The heminested PCR-
A was highly sensitive and specific; however, with clinical sam-
ples, the 120-bp agarose band was sometimes very weak. The
improved nested PCR-B was designed with OLIGO software
(21). Outer primers BBSCH31-BBSCH42 were modified from
the outer primers of the nested PCR-A, and inner primers were
modified from the work of Picken (19). Both annealing temper-
atures of nested PCR-B could be increased with this modification.
Carryover contamination may be a problem, especially in
nested PCR. In order to follow known recommendations for
avoiding contamination (9), the following steps were essential:
(i) parallel testing of high numbers of blank controls, (ii) use of
positive controls with low copy numbers (50 to 100 copies), (iii)
use of oil overlays in the first and second PCRs (iv) use of only
reaction tubes with attached caps, not microtiter plates sealed
with either adhesives or thermoplastic cover sheets and no cap
strips, and (v) use of a DNA extraction procedure with as few
handling steps as possible. In the present study such precau-
tions were apparently efficient, since urine from only 3 of 62
control subjects was reactive.
TABLE 2. Clinical and laboratory data for patients with EM after antibiotic therapya
Patient
no.
Directly after therapy 8 wk after therapy 20 wk after therapy
Appear-
ance of
EM
Additional
signs and
symptoms
S Bb
IgG Ab
S Bb
IgM Ab
Bb DNA
in urine
specimen
Appear-
ance of
EM
Additional
signs and
symptoms
S Bb
IgG Ab
S Bb
IgM Ab
Bb DNA
in urine
specimen
Appear-
ance of
EM
Additional
signs and
symptoms
S Bb
IgG Ab
S Bb
IgM Ab
Bb DNA
in urine
specimen
1 RE N 1 2 2 C N ND ND 2 C N 1 2 ND
2 RE N ND ND ND C N ND ND ND C N ND ND ND
3 RE N 2 2 ND C N ND ND 2 C N 2 1 2
4 RE N 2 2 1 — — — — — — — — — —
5 RE N 2 2 ND RE N ND ND ND C N 1 2 ND
6 RE N 2 2 2 RE N ND ND 2 C N 2 1 2
7 RE N 1 2 1 C N 1 2 ND — — — — —
8 C N 2 1 1 C N 2 2 ND C N 2 2 ND
9 C N 2 2 2 C N ND ND 2 C N 2 2 2
10 RE N 2 2 1 C N ND ND 2 C N 2 2 ND
11 C N 1 2 1 — — — — — — — — — —
12 C N 1 2 2 C N ND ND ND — — — — —
13 C N ND ND ND C N 1 2 2 — — — — —
14 RE N 2 2 1 C N ND ND 2 — — — — —
15 C N 1 2 1 C N ND ND 1 — — — — —
16 RE H 1 2 1 C N ND ND 1 C N 1 2 2
17 C N 2 2 2 C N ND ND 2 — — — — —
18 RE A 2 2 1 C N ND ND 2 — — — — —
19 RE H 2 2 2 C N 2 2 2 C N 2 2 ND
20 RE H 2 2 1 C N ND ND 2 C N 2 2 2
21 C N 1 2 2 C N ND ND 2 C N 2 2 2
22 RE N 1 2 ND — — — — — — — — — —
23 RE N 2 2 1 C N ND ND 2 — — — — —
24 RE N 2 2 2 C N 2 ND ND C N 2 2 2
25 RE H ND ND ND — — — — — — — — — —
26 RE F 2 2 ND C N ND ND 2 — — — — —
a Abbreviations: RE, residual erythema (faded, diminished); C, EM completely cleared; N, none; H, headache; A, arthralgias; F, fatigue; S, serum; Bb, B. burgdorferi;
Ab, antibodies; ND, not done; —, loss from follow-up. A total of 26 patients were examined.
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Urine is known to contain inhibitors of Taq polymerase (4).
Recently, inhibition was seen in 7 of 10 urine samples (7). We
have seen inhibition only for urine from 2 of 26 patients. The
advantage may be due to the incorporation of the Chelex-100
resin (28) in the DNA preparation and to the nested PCR: by
transferring only 1/20 of the reaction mixture of the first PCR
mixture into the second PCR mixture, possible inhibitors were
also diluted out to the same extent.
Our urine PCR was positive for 22 of 24 untreated patients
with EM (sensitivity, 91.67%). Comparison of the reactivity of
the urine PCR with that of serological testing in our patients
with EM reveals a substantial lack of correlation. Of the 22
patients with a positive urine PCR result, sera from only 8
patients (36%) showed increased IgG antibody titers to B.
burgdorferi by ELISA. Three of these eight patients (14%) also
had IgM antibodies. Thus, B. burgdorferi in 14 serology nega-
tive patients could be diagnosed only by urine PCR. On the
other hand, only one patient (patient 25) showed a positive
serology result but a negative PCR result.
Eight weeks after therapy, 2 of 16 patients (13%) had a
reactive urine PCR. Interestingly, these two patients were com-
pletely healthy, whereas one patient with residual erythema (pa-
tient 6) already had a negative urine PCR result. Apart from
these three patients, there was complete correlation between
the patient’s clinical condition and the PCR results. Twenty
weeks after treatment, none of seven investigated urine sam-
ples from then clinically healthy patients was reactive.
On the basis of the results of our study, the following con-
clusions can be drawn. (i) B. burgdorferi-specific DNA can be
detected sensitively in urine specimens of patients with EM by
the nested PCR procedure described here. (ii) Urine PCR
appears to be a sensitive and specific diagnostic tool for early
LB. However, negative results do not rule out actual LB. (iii)
Urine PCR for B. burgdorferi can be reactive within the first
week of the presence of EM. (iv) PCR results become negative
weeks after adequate antibiotic treatment. Urine PCR might
therefore be a useful method for long-term monitoring of the
efficacy of antibiotic therapy for patients with EM, but it can-
not substitute for clinical judgment.
Additional studies with larger numbers of patients and in-
vestigations at different times during and after therapy are
needed to further assess the use of urine PCR as a diagnostic
tool for early LB.
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